MetaCap

Genmab A/S (GMAB) vs Takeda Pharmaceutical (TAK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Genmab A/S (GMAB) has outperformed Takeda Pharmaceutical (TAK) over the past year, gaining 66.2% versus a gain of 52.2%. Over five years, TAK leads with a +60.9% price change compared with +29.1% for GMAB. Takeda Pharmaceutical is the larger company by market cap ($69.55 billion vs $31.20 billion), about 2.2 times the size.

On valuation, Genmab A/S trades at a lower forward P/E (32.0x vs 41.1x for Takeda Pharmaceutical). Takeda Pharmaceutical pays a dividend yielding 927.88%, while Genmab A/S does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GMAB+66.17%TAK+52.24%
+94%+33%-27%
Nov 21, 20251 yearNov 20, 2026
GMAB+22.02%TAK+55.39%
+61%-0%-61%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GMAB versus TAK key metrics
MetricGMABTAK
Share price$50.60$21.77
Market cap$31.20B$69.55B
1-day change-1.46%+1.68%
YTD return+64.29%+39.64%
1-year return+66.17%+52.24%
5-year return+29.15%+60.90%
P/E ratio (TTM)43.25311.00
Forward P/E32.0341.08
EPS (TTM)$1.17$0.07
Dividend yield0.00%927.88%
Annual dividend$0.00$202.00
Revenue (latest FY)$3.72B—
Revenue growth (YoY)+19.19%—
Net income (latest FY)$963.00M—
Gross margin93.60%—
Operating margin28.63%—
Net margin25.89%—
52-week high$59.97$22.07
52-week low$23.62$14.16
Distance from 52-week high-15.62%-1.36%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+28.48%+12.68%
Average volume4.18M2.73M
Shares outstanding616.59M3.19B
Employees3,24447,029
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Takeda Pharmaceutical is about 2.2 times larger than Genmab A/S by market value ($69.55B vs $31.20B).
  • GMAB has outperformed TAK by 13.9 percentage points over the past year.
  • Takeda Pharmaceutical trades at a higher earnings multiple (311.0x vs 43.2x trailing P/E).
  • Takeda Pharmaceutical offers a meaningfully higher dividend yield (927.88% vs 0.00%).

About Genmab A/S

GMAB stock →

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.

Health Care · Biotechnology: Pharmaceutical Preparations · 3,244 employees

About Takeda Pharmaceutical

TAK stock →

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.

Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees

GMAB vs TAK FAQ

Which is bigger, Genmab A/S or Takeda Pharmaceutical?

Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $69.55B compared with $31.20B for Genmab A/S (GMAB).

Which stock has performed better over the past year, GMAB or TAK?

GMAB returned +66.17% over the past 12 months, compared with +52.24% for TAK (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, GMAB or TAK?

GMAB has the lower trailing P/E at 43.2, versus 311.0 for TAK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Genmab A/S or Takeda Pharmaceutical?

Takeda Pharmaceutical pays a dividend yielding 927.88%, while Genmab A/S does not currently pay a regular dividend.

Are Genmab A/S and Takeda Pharmaceutical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons